Micafungin is a glucan synthesis inhibitor of the echinocandin structural class and can be used safely alongside other drugs such as HIV and transplant drugs.
As a semisynthetic lipopeptide Micafungin is an antifungal agent. Micafungin works by inhibiting the enzyme needed for fungal cell-wall synthesis.
In vitro Micafungin is highly protein bound with the primary binding protein being albumin. The half-life of Micafungin is between 14 and 17 hours.
Dose-limiting toxicity has not been found in adult patient clinical trials. The minimum lethal dose of Micafungin is 125 mg/kg in rats, which is 8.1 times the recommended clinical human dose. Severe adverse effects from Micafungin are uncommon, with patients reporting minor side effects like headache, mild itching, slight nausea and flushing.